Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14430453 | 0.95 | MAPK1 (0.36) | MAPK1SMN1; SMN2AKR1B1ALDH1A1 | |
| SCHEMBL14430450 | 0.89 | MAPK1 (0.39) | MAPK1SMN1; SMN2 | |
| SCHEMBL14430444 | 0.89 | MAPK1 (0.39) | MAPK1SMN1; SMN2 | |
| SCHEMBL14430458 | 0.85 | MAPK1 (0.37) | MAPK1SMN1; SMN2 | |
| SCHEMBL14430459 | 0.83 | MAPK1 (0.37) | MAPK1SMN1; SMN2 | |
| SCHEMBL14430457 | 0.82 | MAPK1 (0.36) | MAPK1SMN1; SMN2AKR1B1 | |
| SCHEMBL14441443 | 0.81 | MAPK1 (0.34) | MAPK1SMN1; SMN2 | |
| SCHEMBL5201301 | 0.80 | MAPK1 (0.41) | MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5199451 | 0.80 | MAPK1 (0.41) | MAPK1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL14441447 | 0.79 | MAPK1 (0.34) | MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | claimed |
| EP-1795524-A1 | CYCLIC AMINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-06-13 | — | — | EP | claimed |
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1795524-A1 | CYCLIC AMINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | GRIN1, PARK7, GRIN3A | MAPK1 664/4885SMN1; SMN2 46/4885AKR1B1 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.